Through Indivumed’s state-of-the-art commercial research laboratory, extensive tumor biopsy collection, our direct clinical access to patients, and our biobank – controlled for pre-analytical variables – we are able to facilitate the development of personalized medicines to meet all your oncology laboratory needs.
Our laboratory team is made up of authorities in assay development and biomarker validation, applying cutting-edge genomic and proteomic expertise to guide our support of your research project. By utilizing our comprehensive range of techniques, training, and capability, you can rest safe in the knowledge that you are getting the very best services available to produce the most transformative research results.
Indivumed provides high-quality immunohistochemistry (IHC) services embedded in an ISO-certified company and a GCLP-compliant environment. This includes prevalence studies, validation of biomarkers, targets, or antibodies; with either Indivumed's own tissue samples, biospecimen from Indivumed-qualified external resources using a “pathoscoring system” (real-world tissue), or samples provided by customers.
Based on the Ventana® Discovery and Benchmark Technology, Indivumed has established automated staining protocols for numerous proteins in FFPE specimens, as well as frozen tissue with a special emphasis on phosphoproteins. Customized IHC protocol development with commercially available antibodies or research antibodies can be performed according to a customer’s specialized needs.
Additionally, customers receive a comprehensive report package including (but not limited to) high-quality digital images and an interpretation of the staining patterns by experienced staff pathologists. Quantification of staining results by automated image analysis and verification of results by a pathologist are available on request.